7 Types of Cough Medicine Testing: Product Quality, Safety, and Effectiveness
Cough medicines are available as syrups, suspensions, oral drops, tablets, and capsules. Their formulations may contain different active ingredients depending on whether the product is intended to suppress coughing, support mucus clearance, or relieve accompanying respiratory symptoms.
However, listing an active ingredient on the label does not by itself demonstrate product quality. Manufacturers need to verify that the ingredient is present at the appropriate concentration, remains stable during storage, and is not accompanied by unacceptable chemical or microbial contamination.
For this reason, cough medicine testing is essential for confirming product quality, safety, and consistency before market release.
Table of Content:
- Why Should Cough Medicines Be Tested?
- Active-Ingredient Identification and Assay
- Physical Quality Testing
- DEG and EG Contamination Testing
- Microbiological Quality
- Preservative Effectiveness
- Stability Testing
- Safety Evaluation
Why Should Cough Medicines Be Tested?
The quality of cough medicines may be influenced by raw materials, pharmaceutical water, excipients, manufacturing conditions, preservatives, packaging, temperature, humidity, and light.
According to ICH Q6A, finished pharmaceutical product specifications should include suitable analytical procedures and justified acceptance criteria. The selected tests should reflect the active substance, dosage form, production process, and identified product risks.
Read Also:
Understanding Types of Medicines: Which Ones Require a Doctor’s Prescription?
Active-Ingredient Identification and Assay
Identity testing confirms that the product contains the intended active ingredient. Assay testing then determines whether its actual concentration meets the established specification.
Depending on the formulation, suitable methods may include HPLC, GC, spectrophotometry, or other validated analytical techniques. Analytical procedures should be validated to demonstrate that they are suitable for their intended purpose.
ICH Q2(R2) describes characteristics such as accuracy, precision, specificity, linearity, and range that may be considered during method validation.
Physical Quality Testing
Physical parameters can influence dose accuracy, product stability, and user acceptability. Relevant assessments may include:
- appearance and odor;
- clarity;
- pH;
- viscosity;
- fill volume;
- homogeneity; and
- packaging compatibility.
Suspension products may also require evaluation of sedimentation, particle size, redispersibility, and uniformity after shaking. Poor redispersion could result in unequal active-ingredient distribution between doses.
The suitability of measuring spoons, cups, oral syringes, or other dosing devices should also be considered because they directly affect the administered volume.
DEG and EG Contamination Testing
Liquid medicines may contain excipients such as glycerin, propylene glycol, polyethylene glycol, or sorbitol. These materials should meet pharmaceutical-grade purity requirements.
WHO has reported multiple incidents involving liquid medicines contaminated with diethylene glycol and ethylene glycol. These substances are toxic and have been associated with severe injury and deaths, particularly among children.
WHO identifies gas chromatography as a suitable and widely used technique for accurately testing DEG and EG in pharmaceutical products. These incidents demonstrate the importance of supplier qualification, raw-material testing, traceability, and finished-product verification.
Microbiological Quality
Liquid cough medicines are generally nonsterile products. They are not required to be completely free of microorganisms, but their microbial levels and specified organisms must comply with established requirements.
Testing may include microbial enumeration and examination for relevant specified microorganisms. USP states that microbiological examination of nonsterile products is designed to determine whether a preparation complies with its established microbiological-quality specification.
Preservative Effectiveness
Multidose liquid products may be exposed to contamination each time the bottle is opened or the dosing device is used. Preservative effectiveness testing evaluates whether the formulation’s antimicrobial protection can control introduced microorganisms throughout the intended period of use.
The result helps determine whether the type and concentration of preservative are adequate for the formulation.
Stability Testing
ICH Q1A(R2) describes stability testing as a means of generating evidence on how the quality of a drug substance or finished product changes over time under the influence of environmental factors such as temperature, humidity, and light.
A stability program for cough medicine may evaluate:
- active-ingredient content;
- degradation products;
- pH and viscosity;
- color and odor;
- clarity or sedimentation;
- microbiological quality; and
- packaging integrity.
The resulting data support shelf-life assignment, storage conditions, and finished-product specifications.
Safety Evaluation
Cough medicine safety depends on more than the active ingredient. Excipients, impurities, degradation products, chemical contaminants, microbial quality, dosage accuracy, labeling, and intended users should also be considered.
Depending on the product, safety evaluation may include raw-material purity testing, contaminant analysis, toxicological review, degradation-product assessment, and verification of dosage instructions and warnings.
How Is Product Effectiveness Demonstrated?
Quality-control testing verifies that the product contains the correct active ingredient at the intended concentration and is manufactured consistently. However, an assay result alone does not prove clinical effectiveness.
Claim substantiation may depend on the active ingredient, dose, dosage form, indication, established scientific evidence, and applicable regulatory pathway. Some products may rely on established monographs or approved active ingredients, while others may require pharmacological, bioavailability, bioequivalence, or clinical evidence.
Laboratory testing therefore supports product quality and consistency, while appropriate regulatory or clinical evidence supports the therapeutic claim.
Verify Cough Medicine Quality and Safety with IML
Do not wait until quality problems occur during registration, production, or market distribution. Consult IML Testing & Research to determine the appropriate testing strategy for your cough medicine.
Testing may include active-ingredient assay, physical characterization, stability, microbiological quality, preservative effectiveness, and relevant chemical-contaminant analysis. Reliable laboratory data can support formulation development, technical documentation, registration readiness, and product credibility.
Author & Editor: Lina
References
International Council for Harmonisation. (1999). ICH Q6A: Specifications—Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances.
International Council for Harmonisation. (2023). ICH Q2(R2): Validation of Analytical Procedures.
International Council for Harmonisation. (2003). ICH Q1A(R2): Stability Testing of New Drug Substances and Products.
World Health Organization. (2023). Tests for Diethylene Glycol and Ethylene Glycol in Liquid Oral Dosage Forms.
World Health Organization. (2023). Diethylene Glycol and Ethylene Glycol Contamination: Analytical Methods Developed for Testing Paediatric Medicines.
World Health Organization. (2024). Good Manufacturing Practices for Excipients Used in Pharmaceutical Products.
United States Pharmacopeia. General Chapter <2>: Oral Drug Products—Product Quality Tests.
United States Pharmacopeia. General Chapter <61>: Microbial Enumeration Tests.
United States Pharmacopeia. General Chapter <62>: Tests for Specified Microorganisms.
Badan Pengawas Obat dan Makanan Republik Indonesia. (2022–2023). Penjelasan Publik Perkembangan Pengawasan Sirup Obat yang Mengandung Cemaran Etilen Glikol dan Dietilen Glikol.
